Company
Therapeutic Areas
Our Pipeline
News
Careers
Contact Us
Select Year
2024
2023
2024.05.10
Optimized Artificial miRNAs Delivered by rAAV9 Dramatically Improve Survival, Respiratory and Motor Functions of SOD1(G93A)-ALS Mice
Identification of Artificial microRNAs Targeting C9orf72 Sense and Antisense Transcripts for ALS treatment
2024.05.09
Directed Evolution of Rationally-Engineered AAV Capsid Variants with Enhanced Central Nervous System (CNS) Tropism Following Systematic Administration
2024.05.08
Discovering rationally-engineered AAV5-derived capsid variants for superior CNS tropism and peripheral tissue de-targeting in non-human primate via systemic administration
2023.11.13
A Selective M4 Receptor Positive Allosteric Modulator for the Treatment of Schizophrenia
2023.10.25
Optimized Artificial miRNAs Delivered by AAV9 Dramatically Improve Survival, Respiratory and Motor Functions of SOD1G93A-ALS Mice
About Us
Mission & Culture
Leadership Team
Depression
Schizophrenia
Neurological Disorders
Pipeline
Clinical Trials
Publications
Copyright © 2025 NeuShen Therapeutics, Inc. All rights reserved.